Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Pipeline
  • Pharma Pipeline Stalls for First Time in Decades: Citeline
  • Pipeline

Pharma Pipeline Stalls for First Time in Decades: Citeline

BioSpace

Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an upward trend in investigational assets.

PipelineRead full story

pharminent April 6, 2026 (Last updated: April 6, 2026)

BioSpace

Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an upward trend in investigational assets.

PipelineRead full story

Post navigation

Previous: The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)
Next: Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal

Related Stories

  • Pipeline

Beyond GLP1s: The race for nextgen obesity drugs starts in the preclinical models

pharminent September 2, 2026
  • Pipeline

Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail

pharminent August 25, 2026
  • Pipeline

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

pharminent August 11, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.